A new cervical cancer treatment is showing promise in boosting survival rates and reducing recurrence What this breakthrough means for patients.

Cervical cancer is the fourth most common cancer among women worldwide. In India, where it is the second most common, it ...

Even when she was the most ill, her mother said, her daughter remained more focused on the well-being of those around her than her own suffering. “I think she never wanted to be down around me because ...

A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...

Cervical cancer is caused by human papillomavirus HPV and has become a major health concern Read this article to know ...

Joining a clinical trial for cervical cancer opens the door to new treatments that could have life-changing effects.

One of the key findings in recent studies is the superior diagnostic capability of FDG PET-CT compared to MRI in detecting recurrent cervical cancer after radiotherapy. A study showed that FDG PET ...

Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...

Cervical cancer is a major health issue for Indian women, primarily caused by HPV. Key symptoms include abnormal bleeding and pelvic pain. Preventive measures such as HPV vaccination, safe sex, and ...

In Europe, meanwhile, Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) is indicated as a second-line therapy for recurrent or advanced cervical cancer, regardless of PD-L1 expression status, ...

Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...